BACKGROUND/ OBJECTIVE: Patients with spinal cord injury (SCI) are at risk of acquiring colonization with Clostridium difficile and vancomycin-resistant Enterococcus (VRE) due to prolonged hospitalization and frequent antimicrobial use. We examined the frequency of stool, skin, and environmental contamination with C. difficile and VRE in hospitalized patients with SCl. METHODS: We performed a cross-sectional study of 22 hospitalized patients with SCI with no symptoms of C. difficile infection. Stool samples, skin, and environmental sites were cultured for C. difficile and VRE, and polymerase chain reaction ribotyping was performed for C. difficile isolates. Fisher's exact test was used to compare the proportions of skin and environmental contamination among stool carriers and non-carriers. Univariate analysis was used to assess factors associated with asymptomatic carriage of C. difficile. RESULTS: Of 22 asymptomatic patients, 11 (50%) were asymptomatic carriers of toxigenic C. difficile and 12 (55%) were carriers of VRE. In comparison with non-carriers, asymptomatic carriers of toxigenic C. difficile had higher rates of skin (45 versus 9%) (P = 0.07) and environmental contamination (55 versus 9%) (P = 0.03) and longer length of stay (median, 57 versus 6 days; P = 0.04). A majority of skin and environmental C. difficile isolates from individuals were identical to isolates from stool. In comparison with non-carriers, patients with VRE stool colonization had non-significant trends toward more frequent skin (27 versus 9%) and environmental (18 versus 9%) contamination. CONCLUSION: Asymptomatic stool carriage of toxigenic C. difficile and VRE was common on an acute-care SCI unit. Asymptomatic carriers of toxigenic C. difficile had frequent skin and environmental contamination, suggesting the potential to contribute to transmission.
BACKGROUND/ OBJECTIVE:Patients with spinal cord injury (SCI) are at risk of acquiring colonization with Clostridium difficile and vancomycin-resistant Enterococcus (VRE) due to prolonged hospitalization and frequent antimicrobial use. We examined the frequency of stool, skin, and environmental contamination with C. difficile and VRE in hospitalized patients with SCl. METHODS: We performed a cross-sectional study of 22 hospitalized patients with SCI with no symptoms of C. difficileinfection. Stool samples, skin, and environmental sites were cultured for C. difficile and VRE, and polymerase chain reaction ribotyping was performed for C. difficile isolates. Fisher's exact test was used to compare the proportions of skin and environmental contamination among stool carriers and non-carriers. Univariate analysis was used to assess factors associated with asymptomatic carriage of C. difficile. RESULTS: Of 22 asymptomatic patients, 11 (50%) were asymptomatic carriers of toxigenic C. difficile and 12 (55%) were carriers of VRE. In comparison with non-carriers, asymptomatic carriers of toxigenic C. difficile had higher rates of skin (45 versus 9%) (P = 0.07) and environmental contamination (55 versus 9%) (P = 0.03) and longer length of stay (median, 57 versus 6 days; P = 0.04). A majority of skin and environmental C. difficile isolates from individuals were identical to isolates from stool. In comparison with non-carriers, patients with VRE stool colonization had non-significant trends toward more frequent skin (27 versus 9%) and environmental (18 versus 9%) contamination. CONCLUSION: Asymptomatic stool carriage of toxigenic C. difficile and VRE was common on an acute-care SCI unit. Asymptomatic carriers of toxigenic C. difficile had frequent skin and environmental contamination, suggesting the potential to contribute to transmission.
Authors: Vivian G Loo; Louise Poirier; Mark A Miller; Matthew Oughton; Michael D Libman; Sophie Michaud; Anne-Marie Bourgault; Tuyen Nguyen; Charles Frenette; Mirabelle Kelly; Anne Vibien; Paul Brassard; Susan Fenn; Ken Dewar; Thomas J Hudson; Ruth Horn; Pierre René; Yury Monczak; André Dascal Journal: N Engl J Med Date: 2005-12-01 Impact factor: 91.245
Authors: Michelle M Riggs; Ajay K Sethi; Trina F Zabarsky; Elizabeth C Eckstein; Robin L P Jump; Curtis J Donskey Journal: Clin Infect Dis Date: 2007-09-04 Impact factor: 9.079
Authors: Carlene A Muto; Mary Kathleen Blank; Jane W Marsh; Emanuel N Vergis; Mary M O'Leary; Kathleen A Shutt; Anthony W Pasculle; Marian Pokrywka; Juliet G Garcia; Kathy Posey; Terri L Roberts; Brian A Potoski; Gary E Blank; Richard L Simmons; Peter Veldkamp; Lee H Harrison; David L Paterson Journal: Clin Infect Dis Date: 2007-10-09 Impact factor: 9.079
Authors: Lona Mody; Carol A Kauffman; Susan Donabedian; Marcus Zervos; Suzanne F Bradley Journal: Clin Infect Dis Date: 2008-05-01 Impact factor: 9.079
Authors: Wafa N Al-Nassir; Ajay K Sethi; Michelle M Nerandzic; Greg S Bobulsky; Robin L P Jump; Curtis J Donskey Journal: Clin Infect Dis Date: 2008-07-01 Impact factor: 9.079
Authors: Lona Mody; Shweta Maheshwari; Andrzej Galecki; Carol A Kauffman; Suzanne F Bradley Journal: J Am Geriatr Soc Date: 2007-12 Impact factor: 5.562
Authors: Brittany C Eckstein; Daniel A Adams; Elizabeth C Eckstein; Agam Rao; Ajay K Sethi; Gopala K Yadavalli; Curtis J Donskey Journal: BMC Infect Dis Date: 2007-06-21 Impact factor: 3.090
Authors: Margaret A Fitzpatrick; Katie J Suda; Nasia Safdar; Stephen P Burns; Makoto M Jones; Linda Poggensee; Swetha Ramanathan; Charlesnika T Evans Journal: J Spinal Cord Med Date: 2017-02-15 Impact factor: 1.985
Authors: John F Kokai-Kun; Chenxiong Le; Kenneth Trout; Julia L Cope; Nadim J Ajami; Andrew J Degar; Sheila Connelly Journal: Infect Drug Resist Date: 2020-07-22 Impact factor: 4.003
Authors: Meredith C Faires; David L Pearl; Olaf Berke; Richard J Reid-Smith; J Scott Weese Journal: BMC Infect Dis Date: 2013-07-24 Impact factor: 3.090
Authors: Luis Furuya-Kanamori; John Marquess; Laith Yakob; Thomas V Riley; David L Paterson; Niki F Foster; Charlotte A Huber; Archie C A Clements Journal: BMC Infect Dis Date: 2015-11-14 Impact factor: 3.090